IMRX immuneering.com: Enterprise Value to EBITDA Ratio

This daily price chart for Immuneering Corporation (IMRX) with the 0.00 indicator complements the profile of a firm that unites bioinformatics and oncology specialists to achieve medical breakthroughs. The business relies on a powerful array of biological data and analytical software to design targeted drugs. Meanwhile, the synthesis of basic compounds is delegated to external CRO partners, which minimizes operating expenses and accelerates the discovery of new molecules.

IMRX (Immuneering Corp) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/14/2026

Comprehensive metric breakdowns and analytics for immuneering.com (IMRX)

- stock price and consensus target price:

Stock Quotes Immuneering Inc.|IMRX - Average Forecast Price

- company stock capitalization data:

Market Valuation Immuneering Corp.|IMRX - Value Adjusted for Debt and Cash

- business book valuation details:

Accounting Value per Share Immuneering|IMRX - Total Net Assets|Market Capitalization to Book Value Ratio immuneering.com|IMRX - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

IMRX - Company Net Income|Projected Future Earnings Immuneering Corporation|IMRX - Price to Earnings Multiple|Projected Price to Earnings Immuneering Corporation|IMRX - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Immuneering Corp.|IMRX - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Immuneering|IMRX - Earnings per share for the trailing year|Quarterly EPS earnings growth immuneering.com|IMRX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Immuneering Corporation

- issuer revenue and sales details:

IMRX - Company Sales Revenue|Projected Sales Volume Immuneering Inc.|IMRX - P/S Multiple|Price-to-Projected Revenue Ratio Immuneering Corp.

Basic company analysis:Immuneering Inc. IMRX

Immuneering Corporation (IMRX) is developing an R&D pipeline of MAPK inhibitors for the treatment of pancreatic cancer. Analyzing the EV/EBITDA multiple trajectory allows for an assessment of the total enterprise value, accounting for all liabilities relative to operating profit before taxes. This metric measures the payback period of assets while excluding the influence of capital structure and tax regimes. For the biotechnology sector, this is a key tool for the fundamental valuation of investment efficiency in innovation.

Competitor analysis

Genmab US - Enterprise Value to EBITDA Ratio|Exelixis Inc. (EXEL) - Company Value to EBITDA|NUVL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KYMR (kymeratx.com)|IDYA (IDEAYA Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|ELVN: Enterprise Value to Operating Income Before Depreciation Ratio|ORIC (ORIC Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Relay Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nurix Therapeutics (NRIX)|TYRA (tyra.bio) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VSTM (Verastem)|Enterprise Value to EBITDA Multiple Monte Rosa Therapeutics Inc|Cullinan Therapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA C4 Therapeutics Corp|BDTX (Black Diamond) - Enterprise Value to EBITDA Ratio|RPTX: Enterprise Value to Operating Income Before Depreciation Ratio|PMVP (PMV Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Karyopharm KPTI|EV/EBITDA Multiple PPCB|Cyclacel - Enterprise Value to Operating Income Before Depreciation|Aadi Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALRN|BPMC: Enterprise Value to EBITDA Ratio|GlycoMimetics, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SWTX: EV/EBITDA Multiple